ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2019. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $17,732,000 | -17.0% | 441,649 | -4.9% | 3.89% | -42.3% |
| Q4 2018 | $21,374,000 | -59.9% | 464,649 | -61.3% | 6.74% | -52.6% |
| Q3 2018 | $53,248,000 | +13.2% | 1,200,100 | 0.0% | 14.21% | +86.0% |
| Q2 2018 | $47,032,000 | +288.0% | 1,200,100 | +616.1% | 7.64% | +55.3% |
| Q1 2018 | $12,121,000 | -16.3% | 167,587 | -42.0% | 4.92% | -42.0% |
| Q4 2017 | $14,490,000 | 0.0% | 289,100 | 0.0% | 8.49% | +12.7% |
| Q3 2017 | $14,490,000 | -7.9% | 289,100 | -15.0% | 7.53% | -24.1% |
| Q2 2017 | $15,740,000 | +31.1% | 340,100 | 0.0% | 9.92% | +77.2% |
| Q1 2017 | $12,009,000 | – | 340,100 | – | 5.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |